Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial
There remains a major unmet need for more effective adjuvant therapies for resectable BTC. If this study demonstrates that adding tislelizumab enhances the therapeutic efficacy of capecitabine, this combined regimen will potentially improve the prognosis of patients with resectable BTC. In addition, we will analyze the relationship between various gene expression profiles and clinical endpoint events to define the ideal patient population receiving adjuvant immunotherapy.
Authors
- Shuqun Cheng (ORCID: https://orcid.org/0000-0001-6760-7470)
- Xubiao Wei (ORCID: https://orcid.org/0000-0002-4300-9676)
- Xiaofei Ye (ORCID: https://orcid.org/0000-0003-3692-1285)
- Yabo Jiang
- Yaxin Zheng
- Dong Qu
- Hongkun Zhou (ORCID: https://orcid.org/0000-0001-8047-7893)
- Jinxue Zhou (ORCID: https://orcid.org/0000-0003-4852-6274)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Second Military Medical University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- First Hospital of Jiaxing (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-25
- DOI
- https://doi.org/10.1186/s12885-025-14367-7
- Citations
- 2
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Natural Science Foundation of China